Table 1.
Recent reviews in drug delivery.
| Subject | Article title | Year | Ref. |
|---|---|---|---|
| General drug delivery reviews |
Novel drug delivery systems for retinal diseases. A review. | 2009 | [1] |
| Review of ocular drug delivery. | 2006 | [2] | |
| Sustained-release drug implants for the treatment of intraocular disease. | 2004 | [3] | |
| Sustained transscleral drug delivery. | 2008 | [4] | |
| Current and future ophthalmic drug delivery systems. A shift to the posterior segment. | 2008 | [5] | |
| Recent perspectives in ocular drug delivery. | 2009 | [6] | |
| Drug delivery methods for posterior segment disease. | 2007 | [7] | |
| The origins and evolution of ‘controlled’ drug delivery systems. | 2008 | [8] | |
| Ophthalmic drug delivery: development and regulatory considerations. | 2009 | [9] | |
| Membranes and barriers | Ocular novel drug delivery: impacts of membranes and barriers. | 2008 | [10] |
| Macular disorders | A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials. |
2004 | [11] |
| Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. |
2007 | [12] | |
| Microbubbles | Therapeutic use of ultrasound targeted microbubble destruction: a review of non-cardiac applications. |
2006 | [13] |
| Lipid-based systems | A review of the application of lipid-based systems in systemic, dermal/transdermal and ocular drug delivery. |
2008 | [14] |
| Endophthalmitis | Endophthalmitis: a review of current evaluation and management. | 2007 | [15] |
| Neovascular disease | Anti-vascular endothelial growth factor (VEGF) therapy for ocular neovascular disease. | 2007 | [16] |
| Transporters | Role of transporters in ocular drug delivery system. | 2009 | [17] |